Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by Accountprinceon Jul 11, 2022 11:04am
213 Views
Post# 34815122

RE:With any luck...

RE:With any luck...MM - you've listed all the things that NOW make this worth far more than the $0.80 per share when Baxter first came on board.  Dialco has achieved all it needs to with only DIMI approval to come ("when not if").  AND now that PMX has the Breakthrough Designation it wouldn't surprise me if Baxter moves to acquire the technology now rather than waiting.

Shame they never explained the "Reimbursement - Breakthrough designation" in the AGM presentation.  Does this mean Spectral can expect reimbursement from Baxter for costs?  If so this likely wipes out any need for a raise of funds.  And if options are exercised before the price gets too high (capital gain treatment instead of fully taxed) there'll be more funds in the kitty.  Guess we'll have to wait for our crack disclosure team to explain what "reimbursement" means.  

In any case looks like the requisite achievements for the end game are upon us....
<< Previous
Bullboard Posts
Next >>